PARVORUVAX

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

现在购买

产品特点 产品特点 (SPC)
03-03-2017

有效成分:

INACTIVATED PORCINE PAROVIRUS, K-22 STRAIN, ERYSIPELOTHRIX RHUSIOPATHIAE (LYSED BACTERIAL CELLS), SEROTYPE 2

可用日期:

Merial Animal Health Limited

ATC代码:

QI09AL01

INN(国际名称):

INACTIVATED PORCINE PAROVIRUS, K-22 STRAIN, ERYSIPELOTHRIX RHUSIOPATHIAE (LYSED BACTERIAL CELLS), SEROTYPE 2

剂量:

Unknown

药物剂型:

Suspension for Injection

处方类型:

LM-Licensed Merchant

治疗组:

Porcine

治疗领域:

Inactivated Porcine parvovirus vaccine + inactivated Erysipelothrix vaccine

疗效迹象:

Immunological - Inactivated vaccine

授权状态:

Authorised

授权日期:

2002-05-01

产品特点

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
PARVORUVAX
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 HAI.U: equivalent to HAI antibody titres of 1 log10 in guinea-pigs
after administration of the vaccine.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Gilts, sows and boars.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of breeding pigs (sows, gilts and boars)
against porcine parvovirosis, to reduce the number of
stillbirths and mummified piglets, and against erysipelas to reduce or
prevent clinical symptoms.
The onset of
immunity is obtained from 2 to 3 weeks after the primary vaccination.
A duration of immunity up to 9 months and 11
months following vaccination has been proven for the parvovirus
component and the erysipelas component,
respectively.
4.3 CONTRAINDICATIONS
None
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Primary vaccination against porcine parvovirosis should not be carried
out in the presence of maternally derived antibodies.
Vaccinate only healthy animals.
Each 2-ml dose of vaccine contains:
Inactivated Porcine Parvovirus, K-22 strain
2 HAI.U
_Erysipelothrix rhusiopathiae_ (lysed bacterial cells), serotype 2
1 Elisa U
Aluminium hydroxide (expressed in Al
+++
)
4.2 mg
Thiomersal
0.2 mg
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_6_
_/_
_0_
_2_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_5_
_8_
_5_
                                
                                阅读完整的文件
                                
                            

查看文件历史